WuXi Biologics is committed ... disease project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled manufacturing from 4,000 to 16,000 liters across its ...

Single-use technology manufacturing can attain cost-of-goods that are comparable to stainless-steel systems, noted WuXi.

Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6 ... 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract ...

Revenue: For the year ended December 31, 2024, the Group's revenue grew 9.6% YoY to RMB18,675. ... platforms that accelerate biologics development and manufacturing. Key platforms include WuXia ...

WuXi’s stock has doubled in price since the start of this year, and WuXi Biologics Holdings raised HK$6.1 billion (US$893 ... 30 times its current outsourced manufacturing capacity for ...

The entire clinical development process may last 6-11 years. WuXi’s phase 1 and phase ... can’t manufacture everything in-house. Biologics manufacturing requires quality certificates and ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific ...

SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been ...

HONG KONG, March 25, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269), a leading global Contract Research, Development and Manufacturing ...